Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 8/20 | 0.39 |
| ▸ | KRAS | P01116 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 7/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.33 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29427309 | 0.86 | RAF1 (0.53) | RAF1KRASBRAFKDRABL1 | |
| SCHEMBL22612912 | 0.86 | RAF1 (0.53) | RAF1KRASBRAFKDRABL1 | |
| SCHEMBL22612917 | 0.86 | RAF1 (0.53) | RAF1KRASBRAFKDRABL1 | |
| SCHEMBL22612714 | 0.85 | RAF1 (0.36) | RAF1KRASBRAFKDRABL1 | |
| SCHEMBL22612715 | 0.85 | RAF1 (0.36) | RAF1KRASBRAFKDRABL1 | |
| SCHEMBL29427297 | 0.85 | RAF1 (0.36) | RAF1KRASBRAFKDRABL1 | |
| SCHEMBL26165650 | 0.84 | RAF1 (0.43) | RAF1KRASBRAFKDR | |
| SCHEMBL23745199 | 0.77 | RAF1 (0.55) | RAF1KRASBRAFKDRABL1 | |
| SCHEMBL22625505 | 0.77 | RAF1 (0.55) | RAF1KRASBRAFKDRABL1 | |
| SCHEMBL22625537 | 0.76 | RAF1 (0.54) | RAF1KRASBRAFKDRABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667634-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2023-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667634-B2 | Inhibitors of RAF kinases | BRAF, RAF1, NRAS | RAF1 2/4885KRAS 5/4885BRAF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.